Literature DB >> 26434085

Metabolic Correction as a tool to improve diabetes type 2 management.

Jorge R Miranda-Massari, Michael J Gonzalez, Alvarez-Soto Fernando, Carlos Cidre, Iván M Paz, Jorge Charvel, Viridiana Martínez, Jorge Duconge, Aileen Aponte, Carlos M Ricart.   

Abstract

Diabetes Mellitus type 2 (DM2) is a metabolic disease that develops by a decrease in sensitivity of insulin receptors as an effect of the disruption certain metabolic functions in the processing of glucose. DM2 patients have, uncontrolled glucose levels, and commonly have problems with obesity and cardiovascular disease. Patients are treated with standard diet, insulin, diabetic oral agents and antihypertensive drugs, but this approach does not completely stops tissue deterioration since it does not address the metabolic root of the disease. Metabolic correction is proposed as a suitable adjunct treatment to improve clinical outcomes. Metabolic correction is based on diet modification, proper hydration and scientific supplementation directed to improve cellular biochemistry and metabolic efficiency. In addition, other possible benefits may include reduction in medication use, disease complications and medical costs. To test the results of a metabolic correction program, 25 patients with DM2 participated in an education program about adequate food consumption that promoted control of blood glucose levels. Anthropometric measurements and blood tests were performed during a 13 week program based on a low carbohydrate diet, proper hydration and magnesium supplementation. The metabolic correction program implemented by a proprietary educational system resulted in significant reductions in glucose, triglycerides, cholesterol, weight and waist circumference. Improvements in these values could represent an important reduction of coronary heart disease risk factors as well as other chronic degenerative diseases. In addition there was medication dosage reduction in one or more medications in 21 of the 25 participating patients, which suggest that the program has the potential to improve health outcomes and reduce health care costs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26434085

Source DB:  PubMed          Journal:  Bol Asoc Med P R        ISSN: 0004-4849


  4 in total

1.  Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions.

Authors:  Jorge R Miranda-Massari; José R Rodríguez-Gómez; Michael J González; Carlos Cidre; Jorge Duconge; Heriberto Marín; Kazuko Grace; Howard L McLeod
Journal:  Int J Diabetes Res       Date:  2016

2.  Therapeutic Effects of Adipose Stem Cells from Diabetic Mice for the Treatment of Type 2 Diabetes.

Authors:  Mengmeng Wang; Lili Song; Charlie Strange; Xiao Dong; Hongjun Wang
Journal:  Mol Ther       Date:  2018-06-19       Impact factor: 11.454

3.  Involvement of stanniocalcins in the deregulation of glycaemia in obese mice and type 2 diabetic patients.

Authors:  José Javier López; Isaac Jardín; Carlos Cantonero Chamorro; Manuel Luis Duran; María José Tarancón Rubio; Maria Reyes Panadero; Francisca Jiménez; Rocio Montero; María José González; Manuel Martínez; María Jose Hernández; José María Brull; Antonio Jesús Corbacho; Elena Delgado; María Purificación Granados; Luis Gómez-Gordo; Juan Antonio Rosado; Pedro Cosme Redondo
Journal:  J Cell Mol Med       Date:  2017-10-09       Impact factor: 5.310

4.  Mesenchymal stem cell-derived exosomes exert ameliorative effects in type 2 diabetes by improving hepatic glucose and lipid metabolism via enhancing autophagy.

Authors:  Qin He; Lingshu Wang; Ruxing Zhao; Fei Yan; Sha Sha; Chen Cui; Jia Song; Huiqing Hu; Xinghong Guo; Mengmeng Yang; Yixin Cui; Yujing Sun; Zheng Sun; Fuqiang Liu; Ming Dong; Xinguo Hou; Li Chen
Journal:  Stem Cell Res Ther       Date:  2020-06-08       Impact factor: 8.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.